Upendra Chitgupi

Dr. Upendra Chitgupi

Nektar Therapeutics; Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2016 in Advanced Materials
Verified
Journal Article
Open access
PDF file
YZYumiao Zhang
Yumiao Zhang
DWDepeng Wang
Depeng Wang
SGShreya Goel
Shreya Goel
BSBoyang Sun
Boyang Sun
Upendra ChitgupiUpendra Chitgupi
Upendra Chitgupi
Jonathan LovellJonathan Lovell
Jonathan Lovell
Edible, surfactant‐stripped, frozen micelles are formed from pheophytin (demetallated chlorophyll), a pigment that is naturally consumed in human diets. Pheophytin nanoparticles pass completely and safely through the gastrointestinal tract and enable trimodal gut contrast imaging via photoacoustic, fluorescence, and positron emission tomography techniques.

26 September 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Upendra ChitgupiUpendra Chitgupi
Upendra Chitgupi
YQYiru Qin
Yiru Qin
SGSanjana Ghosh
Sanjana Ghosh
BQBreandan Quinn
Breandan Quinn
KCKevin Carter
Kevin Carter
Jonathan LovellJonathan Lovell
Jonathan Lovell
Light-responsive liposomes have been developed for the on-demand release of drugs. However, efficient delivery of chemotherapeutic drugs to tumor for cancer theranostics remains a challenge. Herein, folic acid (FA), an established ligand for targeted drug delivery, was used to decorate light-sensitive porphyrin-phospholipid (PoP) liposomes, which were assessed for FA-targeted chemophototherapy (CPT). PoP liposomes and FA-conjugated PoP liposomes were loaded with Doxorubicin (Dox), and physical properties were characterized. In vitro, FA-PoP liposomes that were incubated with FA receptor-overexpressing human KB cancer cells showed increased uptake compared to non-targeted PoP liposomes. Dox and PoP contributed towards chemophototherapy (CPT) in vitro, and PoP and FA-PoP liposomes induced cell killing. In vivo, mice bearing subcutaneous KB tumors treated with PoP or FA-PoP liposomes loaded with Dox, followed by 665 nm laser treatment, had delayed tumor growth and improved survival. Dox delivery to tumors increased following laser irradiation for both PoP and FA-PoP liposomes. Thus, while Dox-FA-PoP liposomes were effective following systemic administration and local light irradiation in this tumor model, the FA targeting moiety did not appear essential for anti-tumor responses.

12 April 2018 in Molecules
Verified
Journal Article
Open access
PDF file
Upendra ChitgupiUpendra Chitgupi
Upendra Chitgupi
Jonathan LovellJonathan Lovell
Jonathan Lovell
RVRajendiran Venugopal
Rajendiran Venugopal
Mesotetra(4-carboxyphenyl)porphyrin (mTCPP) is a commercially available small molecule fluorophore and photosensitizer with four free carboxylic acid groups. mTCPP can readily be conjugated with amines for facile attachment of functional groups. In this work, we synthesized and assessed tetravalent, lysine-conjugated mTCPP, for its potential applications in targeted imaging and photodynamic therapy. Fmoc-protected d-lysine or l-lysine was conjugated to mTCPP via amide coupling with the epsilon amine group of lysine, followed by Fmoc deprotection. The resulting compounds did not dissolve well in aqueous solvent, but could be solubilized with the assistance of surfactants, including cholic acid. The l-amino acid transporter (LAT1) can uptake diverse neutral l-amino acids. In vitro studies with U87 cells revealed a non-specific uptake of the hydrophobic Fmoc-protected lysine-conjugated mTCPP precursors, but not d- or l-lysine mTCPP. Likewise, only the Fmoc-protected compounds induced substantial phototoxicty in cells following incubation and irradiation with blue light. These experimental results do not provide evidence to suggest that lysine-mTCPP is able to specifically target cancer cells. However, they do highlight mTCPP as a convenient and accessible framework for assessing molecular targeting of photosensitizers.

12 March 2020 in Advanced Therapeutics
Verified
Journal Article
Open access
PDF file
BSBoyang Sun
Boyang Sun
Upendra ChitgupiUpendra Chitgupi
Upendra Chitgupi
CLChangning Li
Changning Li
JFJasmin Federizon
Jasmin Federizon
CZChangjie Zhang
Changjie Zhang
Jonathan LovellJonathan Lovell
Jonathan Lovell
The cover image representing article number 1900161 by Jonathan F Lovell and co‐workers shows aggregates formed by the anti‐cancer drug cabazitaxel. In this work, it is shown that by co‐formulating cabazitaxel in unique surfactant micelles with certain other hydrophobic cargo, aggregation can be prevented, resulting in a potent chemotherapy formulation with long‐term liquid storage stability and a high drug‐to‐excipient ratio.